Boston Trust Walden Corp Sells 29,818 Shares of Stryker Co. (NYSE:SYK)

Boston Trust Walden Corp decreased its position in shares of Stryker Co. (NYSE:SYK) by 8.2% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 335,123 shares of the medical technology company’s stock after selling 29,818 shares during the quarter. Stryker comprises approximately 0.8% of Boston Trust Walden Corp’s investment portfolio, making the stock its 26th biggest holding. Boston Trust Walden Corp owned about 0.09% of Stryker worth $121,067,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently bought and sold shares of the company. Koshinski Asset Management Inc. acquired a new position in shares of Stryker in the 1st quarter valued at $795,000. Envestnet Portfolio Solutions Inc. raised its holdings in Stryker by 43.1% during the 1st quarter. Envestnet Portfolio Solutions Inc. now owns 18,491 shares of the medical technology company’s stock worth $6,617,000 after buying an additional 5,565 shares during the period. Norden Group LLC bought a new position in Stryker in the first quarter valued at approximately $4,027,000. BI Asset Management Fondsmaeglerselskab A S boosted its holdings in shares of Stryker by 38.5% in the first quarter. BI Asset Management Fondsmaeglerselskab A S now owns 19,796 shares of the medical technology company’s stock valued at $7,084,000 after buying an additional 5,502 shares during the period. Finally, Wealth Enhancement Advisory Services LLC increased its position in shares of Stryker by 78.9% during the second quarter. Wealth Enhancement Advisory Services LLC now owns 133,020 shares of the medical technology company’s stock worth $45,260,000 after acquiring an additional 58,673 shares in the last quarter. Institutional investors and hedge funds own 77.09% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on SYK. Piper Sandler reiterated an “overweight” rating and set a $380.00 target price on shares of Stryker in a report on Tuesday, September 10th. Needham & Company LLC lifted their target price on Stryker from $392.00 to $393.00 and gave the company a “buy” rating in a research report on Thursday, August 1st. Evercore ISI upped their price target on Stryker from $365.00 to $380.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 1st. Truist Financial lifted their price objective on shares of Stryker from $345.00 to $370.00 and gave the company a “hold” rating in a report on Monday, October 14th. Finally, StockNews.com upgraded shares of Stryker from a “hold” rating to a “buy” rating in a report on Tuesday, October 1st. Four equities research analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $381.16.

Stryker Stock Performance

Shares of SYK traded down $7.08 during trading hours on Friday, hitting $352.82. The company had a trading volume of 1,244,464 shares, compared to its average volume of 1,247,738. The firm has a market cap of $134.41 billion, a price-to-earnings ratio of 40.28, a PEG ratio of 2.83 and a beta of 0.91. The company has a quick ratio of 0.95, a current ratio of 1.68 and a debt-to-equity ratio of 0.51. The business has a fifty day moving average of $358.80 and a 200-day moving average of $343.72. Stryker Co. has a 12 month low of $255.22 and a 12 month high of $374.63.

Stryker (NYSE:SYK) last issued its quarterly earnings data on Tuesday, July 30th. The medical technology company reported $2.81 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.79 by $0.02. Stryker had a net margin of 16.12% and a return on equity of 22.89%. The firm had revenue of $5.42 billion during the quarter, compared to the consensus estimate of $5.40 billion. During the same period last year, the business posted $2.54 earnings per share. The business’s revenue for the quarter was up 8.5% compared to the same quarter last year. Equities analysts anticipate that Stryker Co. will post 12 EPS for the current fiscal year.

Stryker Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, October 31st. Shareholders of record on Monday, September 30th will be issued a $0.80 dividend. This represents a $3.20 dividend on an annualized basis and a yield of 0.91%. The ex-dividend date of this dividend is Monday, September 30th. Stryker’s dividend payout ratio is 36.53%.

Insider Transactions at Stryker

In related news, VP M Kathryn Fink sold 2,121 shares of the company’s stock in a transaction dated Friday, September 13th. The shares were sold at an average price of $370.00, for a total value of $784,770.00. Following the transaction, the vice president now directly owns 10,042 shares in the company, valued at approximately $3,715,540. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. In related news, VP M Kathryn Fink sold 2,121 shares of the stock in a transaction that occurred on Friday, September 13th. The stock was sold at an average price of $370.00, for a total transaction of $784,770.00. Following the sale, the vice president now owns 10,042 shares of the company’s stock, valued at $3,715,540. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Ronda E. Stryker sold 190,000 shares of the company’s stock in a transaction on Tuesday, August 6th. The shares were sold at an average price of $323.46, for a total value of $61,457,400.00. Following the sale, the director now owns 3,316,608 shares of the company’s stock, valued at approximately $1,072,790,023.68. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 220,068 shares of company stock valued at $71,811,372. 5.90% of the stock is currently owned by corporate insiders.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.